The global Guillain barre syndrome treatment market is anticipated to grow at a significant CAGR of 5.2% during the forecast period. As per the information provided by the United Nations, in 2020, there are an estimated 727 million persons aged 65 years or over across. Additionally, this number is projected to be more than double by 2050, reaching over 1.5 billion persons. So, the increasing elderly population, which leads to the pervasiveness of immunological illnesses is one of the primary factors driving the expansion of the guillain barre syndrome market.
Further, the key players operating in the global guillain barre syndrome treatment market had been adopting strategies such as new launches and agreements to gain major market share. For instance, in November 2021, Biotest AG announced the authorization in France for the human intravenous immunoglobulin preparation that is Intratect which is manufactured and marketed by Biotest in two concentrations. The Intratect is an important component of Biotest’s portfolio with over 50 approvals globally. The broad spectrum of indications includes substitution therapy for primary and secondary immunodeficiency diseases along with immunomodulation for primary immune thrombocytopenia, Guillain-Barré syndrome, and Kawasaki syndrome, among others. Further, in September 2019, Annexon Biosciences Inc., announced that the FDA had granted fast track designation to ANX005, a novel treatment for Guillain-Barré syndrome. ANX005 is a clinical-stage investigational monoclonal antibody intended to treat patients with autoimmune and neurodegenerative disorders and formulated for IV administration.
To Request a Sample of our Report on Guillain Barre Syndrome Treatment Market: https://www.omrglobal.com/request-sample/guillain-barre-syndrome-treatment-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Type
- By Distribution Channel
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape – including, Bayer AG, Grifols SA, CSL Ltd., Octapharma AG, Kedrion Biopharma Inc., and Takeda Pharmaceutical Co. Ltd., among others.
Guillain Barre Syndrome Treatment Market Report Segment
By Type
- Intravenous Immunoglobulin
- Plasma Exchange
- Others (Anticonvulsants and LMWH)
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
A full Report of Guillain Barre Syndrome Treatment Market is Available @ https://www.omrglobal.com/industry-reports/guillain-barre-syndrome-treatment-market
Guillain Barre Syndrome Treatment Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Company Profiles
- Akari Therapeutics Inc.
- Annexon Biosciences Inc.
- Bayer AG
- Biotest AG
- China Biologic Product Holdings Inc.
- CSL Ltd.
- CuraVac Inc.
- Grifols SA
- Hansa Medical AB
- Kedrion Biopharma Inc.
- Nihon Pharmaceutical Co. Ltd.
- Octapharma AG
- Takeda Pharmaceutical Co. Ltd.
- Vitality Biopharma Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
